According to the research report titled ‘Global Dry Eye Disease (DED) Market - Analysis By Disease (Aqueous, Evaporative, Others), Treatment, End User, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid -19 Impact, Competition and Forecast (2021-2026)’, available with Market Study Report, global dry eye disease (DED) market was valued USD 5378.59 million in 2020 and is expected to record a healthy growth rate over the forecast period 2021-2026.
 

As per the report findings, global dry eye disease (DED) market growth is primarily driven by increasing life expectancy, booming elderly population, burgeoning working population, and rising prevalence of lifestyle with excessive screen time.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3542234/
 

Apart from the aforementioned factors, the document also covers the existing and upcoming challenges as well as the opportunities and associated risks in this domain.
 

In terms of disease, the market is categorized into aqueous, evaporative, and others. Evaporative dry eye disease segment is slated to capture majority industry share in the upcoming year, attributable to recent clinical and epidemiological studies confirming that most dry eye patients mixed evaporative and aqueous deficient dry eye, among which, the former is most common symptom.
 

Moving on to end-users in global dry eye disease (DED) industry, retailers, hospitals, and online are the key segments covered in the research literature. Hospitals, followed by clinics led the industry growth mainly due to rising number of eye disorder cases, and heavy expenditure by pharma companies players towards developing awareness about eye diseases and their implications.
 

Considering the regional analysis, North America (U.S., Canada), Europe (France, U.K., Italy, Germany), Asia Pacific (India, China, South Korea) are the most attractive avenues for business expansion. Experts cite that North America market is touted to grow considerably in the forthcoming years due to high concentration of several leading drug manufacturers, increasing production capacity expansion activities undertaken by them, and proliferating number of people suffering from dry eye disease.
 

Prominent players in worldwide dry eye diseases (DED) market sphere are Sentiss Pharma Pvt Ltd., Novaliq GmbH, Horus Pharma, VISUfarma, Santen Pharmaceutical Co. Ltd., Novartis AG, Allergan plc, Alcon AG, Bausch Health Companies Inc., and Johnson & Johnson.
 

Experts cite that introduction of new products with better functionality and outcomes will continue to play a vital role in dictating the profitability of companies functioning in this domain.